Life Tech Genetic Analysis Revenues Decline as qPCR Royalties Wither, Though QuantStudio Sales Spike | GenomeWeb

Life Technologies this week reported a 6 percent drop in second-quarter revenues for its Genetic Analysis segment, primarily due to dwindling qPCR royalties and a decline in sales of its SOLiD sequencers.

However, excluding these "headwinds," Genetic Analysis revenues increased 5 percent, the company said, driven in part by sales of its Ion Torrent sequencers and "a record number" of its QuantStudio 12K Flex real-time and digital PCR platform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.